SG/PUT/ABBOTT LABORATORIES/100/0.1/20.06.25 Stock

Warrant

DE000SY03QS9

Real-time Bid/Ask 04:00:03 2024-07-11 am EDT
0.69 EUR / 0.73 EUR -1.39% Intraday chart for SG/PUT/ABBOTT LABORATORIES/100/0.1/20.06.25
Current month+20.00%
1 month+33.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-11 0.69 -4.17%
24-07-10 0.72 +4.35%
24-07-09 0.69 +9.52%
24-07-08 0.63 -5.97%
24-07-05 0.67 -1.47%

Delayed Quote Börse Stuttgart

Last update July 11, 2024 at 02:41 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying ABBOTT LABORATORIES
IssuerLogo Issuer Société Générale Société Générale
WKN SY03QS
ISINDE000SY03QS9
Date issued 2024-05-30
Strike 100 $
Maturity 2025-06-20 (345 Days)
Parity 10 : 1
Emission price 0.75
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.75
Lowest since issue 0.54
Spread 0.04
Spread %5.48%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
103 USD
Average target price
124.8 USD
Spread / Average Target
+21.08%
Consensus